However, in RCC, the constitutive activation of Nrf2, resulting from modifications of the KEAP1–Nrf2-CUL3 complex, enhances cancer cell proliferation, survival, metastatic potential, and resistance to therapies [79]. This evidence concerns the gene NFE2L2 and renal cell carcinoma.